Re-evaluating serum IL-6 as a prognostic biomarker in HCC immunotherapy with atezolizumab plus bevacizumab: the critical role of baseline liver function and disease etiology

Annals of Hepatology 2026 Open access

Read full text
Authors: Min Zou, Shiye Yang, Jinkai Feng, Zengqiang Yang
DOI: 10.1016/j.aohep.2026.102195
Cited by: 0
References: 13

Fields of Study & Subjects

Hepatocellular Carcinoma Treatment and Prognosis Cancer Immunotherapy and Biomarkers Colorectal Cancer Treatments and Studies

Publication details

Journal / source
Annals of Hepatology
Volume
31
Issue
1
Pages
102195–102195
Publication date
1 January 2026
Language
EN